Targeting Aging and Promoting Longevity with Exogenous Nucleotides (TALENTs)

Launched by PEKING UNIVERSITY · Feb 7, 2022

Keywords

ClinConnect Summary

To explore the anti-aging effects of NTs and the regulation of aging-related diseases, this study plans to recruit 120 people as subjects and conduct randomized controlled trials with NTs as an intervention for 4 months. Based on computer-generated random numbers, participants who meet the inclusion criteria are randomly assigned equally to two groups: placebo control and nucleotide intervention groups. In this study, the specific nucleotide composition is 5'-AMP、5'-CMP、5'-GMPNa2、5'-UMPNa2 prepared according to the ratio of 16:41:19:24, which is consistent with the ratio in breast milk and ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male/females of 60 to 70 years of age
• • 2. No serious physical or mental illness
• • 3. Able to provide written Informed Consent
• • 4. Able to follow verbal and written study directions
• • 5. Must not be taking or be willing to take any supplements containing any form of nucleotides for one year prior to baseline and for the duration of the study.
• • 6. Able to maintain consistent diet and lifestyle habits throughout the study
• • 7. Willing to consume assigned supplement (NTs or placebo) for 4 months
• Exclusion Criteria:
• • 1. Participants on the current use of prescription or over-the-counter nucleotides
• • 2. Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator
• • 3. Documented presence of atherosclerotic disease and/or cardiopulmonary disease
• • 4. History of drug or alcohol abuse
• • 5. History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements
• • 6. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.
• • 7. Currently, or within the past 30 days, enrolled in a different clinical investigation
• • 8. Inability to provide a venous blood sample
• • 9. Unable or unwilling to provide written informed consent for participation in the study